114 related articles for article (PubMed ID: 29120133)
1. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Sahoo RK; Kumar L
N Engl J Med; 2017 Nov; 377(19):1901-2. PubMed ID: 29120133
[No Abstract] [Full Text] [Related]
2. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
3. [Research Progress on Treating Acute Myeloid Leukemia by Midostaurin].
Wang YY; Sun WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1780-4. PubMed ID: 26708910
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
5. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Eskazan AE
N Engl J Med; 2017 Nov; 377(19):1901. PubMed ID: 29120132
[No Abstract] [Full Text] [Related]
6. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Stone RM; Larson RA; Döhner H
N Engl J Med; 2017 Nov; 377(19):1903. PubMed ID: 29117486
[No Abstract] [Full Text] [Related]
7. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
8. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
9. Midostaurin in FLT3-mutated acute myeloid leukaemia.
Das M
Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
[No Abstract] [Full Text] [Related]
10. Midostaurin for the treatment of acute myeloid leukemia.
Patnaik MM
Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
[TBL] [Abstract][Full Text] [Related]
11. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
Tvedt TH; Nepstad I; Bruserud Ø
Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
14. Midostaurin + Chemo Ups AML Survival.
Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin in acute myeloid leukaemia with a
Sharma A; Bakhshi S
Natl Med J India; 2018; 31(5):288-290. PubMed ID: 31267996
[No Abstract] [Full Text] [Related]
16. Midostaurin Gets FDA Nod for AML.
Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
[TBL] [Abstract][Full Text] [Related]
17. Midostaurin: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
[TBL] [Abstract][Full Text] [Related]
18. Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.
Lipka DB; Wagner MC; Dziadosz M; Fischer T
Leukemia; 2016 Oct; 30(10):2090-2093. PubMed ID: 27137475
[No Abstract] [Full Text] [Related]
19. A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia.
Zwaan CM; Söderhäll S; Brethon B; Luciani M; Rizzari C; Stam RW; Besse E; Dutreix C; Fagioli F; Ho PA; Dufour C; Pieters R
Br J Haematol; 2019 May; 185(3):623-627. PubMed ID: 30203832
[No Abstract] [Full Text] [Related]
20. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Strati P; Kantarjian H; Ravandi F; Nazha A; Borthakur G; Daver N; Kadia T; Estrov Z; Garcia-Manero G; Konopleva M; Rajkhowa T; Durand M; Andreeff M; Levis M; Cortes J
Am J Hematol; 2015 Apr; 90(4):276-81. PubMed ID: 25530214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
